Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kagoshima
Clinical trial register · Japan

Clinical Trials in Kagoshima, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca12 Eli Lilly and Company8 Hoffmann-La Roche6 GlaxoSmithKline6 Pfizer5
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Kagoshima

108 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
NCT07816666Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer
DrugsTorvutatug samrotecan·Bevacizumab
AstraZeneca
Phase 3
600
Chiba, Fukuoka, Fukushima, Gifu, Hidaka-shi, Ichihara, Kagoshima, Kobe
2026-09-24
Recruiting
4D Molecular Therapeutics
Phase 3
514
Mito, Amagasaki-shi, Fukuoka, Fukushima, Hachioji-shi, Kagoshima, Kita-Gun, Kobe
2026-09-18
Recruiting
Incyte Corporation
Phase 3
426
Bunkyō City, Chūō, Fukuoka, Fukushima, Hirakata, Kagoshima, Kashiwa-shi, Kobe
2026-09-08
Recruiting
AstraZeneca
Phase 2
24
Ginowan-shi, Kagoshima, Kanazawa, Niigata
2026-08-31
Recruiting
Pfizer
Phase 3
1,375
Nagoya, Kagoshima, Yokohama, Sakai, Saitama, Chuo-ku, Tachikawa, Toshima-ku
2026-08-24
Recruiting
AstraZeneca
Phase 3
900
Chigasaki-shi, Chikushino-shi, Gifu, Kagoshima, Kitakyushu, Kumamoto, Kyoto, Maebashi
2026-07-06
Recruiting
Pemafibrate for Symptomatic ICAS RCT
NCT07562178Intracranial Atherosclerotic Disease (ICAD), Hypertriglyceridaemia, Stroke (CVA) or TIA
DrugPemafibrate
Tokyo Women's Medical University
Not applicable
270
Toyoake, Yachiyo, Fukuyama, Hiroshima, Kobe, Tsukuba, Hizume, Kagoshima
2026-05-26
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Bunkyō City, Hamamatsu, Higashi-Ibaraki, Kagoshima, Kashiwa, Kumamoto, Minatoku, Mitaka
2026-05-23
Recruiting
BeOne Medicines
Phase 3
1,056
Kurumeshi, Otashi, Hiroshima, Sapporo, Nishinomiyashi, Kagoshima, Iseharashi, Kawasakishi
2026-05-22
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Bunkyō City, Hamamatsu, Hirosaki, Kagoshima, Kashiwa, Kobe, Kumamoto, Minatoku
2026-05-22
Recruiting
Kyowa Kirin Co., Ltd.
Phase 2
6
Chiba, Gifu, Hyōgo, Ibaraki, Kagoshima, Kanagawa, Kyoto, Miyagi
2026-04-23
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
DrugZotemtegrast
Eli Lilly and Company
Phase 2
1,431
Asahikawa, Bunkyō City, Fujiidera, Fukuoka, Hirosaki, Kagoshima, Kashiwa, Mitaka
2026-03-26
Recruiting
MSA-01 in Multiple System Atrophy
NCT07446894Multiple System Atrophy (MSA)
Tokyo University
Phase 3
140
Nagoya, Chiba, Fukuoka, Sapporo, Kagoshima, Kyoto, Okayama, Hasuda
2026-02-09
Recruiting
Sanofi
Phase 3
751
Bunkyō City, Chikushino-shi, Hachiōji, Kagoshima, Kamakura, Kashiwa, Kobe, Kōriyama
2026-01-16
Recruiting
Janssen Research & Development, LLC
Phase 2
240
Fuchū, Kagoshima, Kitakyushu-shi, Osaka, Sanuki, Shimonoseki
2026-01-15
Recruiting
Eli Lilly and Company
Phase 3
800
Bunkyō City, Chiba, Fukuoka, Fukushima, Hidaka, Hirakata, Hiroshima, Kagoshima
2025-12-22
Recruiting
GlaxoSmithKline
Phase 3
1,250
Gunma, Kagoshima
2025-12-12
Active, closed
Kymera Therapeutics, Inc.
Phase 2
200
Ichikawa, Kagoshima, Kanagawa, Nagoya, Osaka, Sakai, Sapporo
2025-11-24
Recruiting
BioNTech SE
Phase 3
558
Bunkyō City, Chiba, Fukushima, Gifu, Hidaka, Hiroshima, Kagoshima, Kōtoku
2025-10-30
Recruiting
Hoffmann-La Roche
Phase 3
600
Aichi, Fukuoka, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Miyagi, Niigata
2025-10-24
Recruiting
Eli Lilly and Company
Phase 2
531
Chūōku, Habikino, Iizuka, Kagoshima, Kanazawa, Katsushika-ku, Nagoya, Narita
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
1,630
Akashi, Chūōku, Fukuoka, Hidaka, Kagoshima, Kashiwa, Kōtoku, Nagoya
2025-10-22
Recruiting
Sanofi
Phase 3
980
Asahikawa, Bunkyō City, Chikushino-shi, Chūō, Fukuoka, Kagoshima, Kamakura, Kanazawa
2025-10-08
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Chiba, Fukui-shi, Gamagōri, Hamamatsu, Higashiibaraki-gun, Hiroshima, Kagawa, Kagoshima
2025-10-03
Recruiting
AbbVie
Observational
700
Maebashi, Asahikawa-shi, Sapporo, Kagoshima, Isehara, Yokohama, Kyoto, Kurashiki
2025-09-09
Recruiting
GlaxoSmithKline
Phase 3
420
Fukuoka, Hokkaido, Ishikawa, Kagoshima, Kanagawa, Kochi, Kyoto, Mie
2025-08-11
Not yet open
Encapsulation-oriented vs. Timing-oriented Strategies for Necrotizing Pancreatitis
NCT07106346Walled Off Necrosis, Pancreatitis, Acute Necrotic Collection, Necrotizing Pancreatitis
Tokyo University
Not applicable
224
Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyōgo, Kagawa, Kagoshima
2025-08-05
Recruiting
Nippon Medical School
Phase 4
500
Chūō, Fukui, Fukuoka, Fukuyama, Hirakata, Kagoshima, Katsuura, Kawasaki
2025-08-01
Recruiting
Joseph Broderick, MD
Phase 3
350
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Niigata, Osaka
2025-05-06
Recruiting
BeOne Medicines
Phase 3
250
Nagoya, Chiba, Matsuyama, Hiroshima, Sapporo, AmagasakiCity, Kagoshima, KyotoShi
2025-04-10
Recruiting
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014
DrugsIBI305·HD204·Bevacizumab-awwb·BP102
NRG Oncology
Phase 3
880
Sendai, Tōon, Kure, Sapporo, Akashi, Shiwa-gun, Kagoshima, Gunma
2025-03-12
Recruiting
Pfizer
Phase 3
723
Kobe, Kyoto-shi Shimogyo-ku, Sendai, Shibuya-ku, Kai, Kagoshima
2025-03-11
Recruiting
AbbVie
Phase 3
420
Kobe, Kochi, Osaka, Shibuya-ku, Shinjuku-ku, Tendo-shi, Kai, Kagoshima
2025-02-13
Active, closed
Ipsen
Phase 3
18
Chiba, Fukushima, Hiroshima, Hokkaido, Kagawa, Kagoshima, Nagano, Nagasaki
2025-01-16
Active, closed
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
Alumis Inc
Phase 3
1,680
Nagoya, Fukuoka, Asahikawa, Ibaraki, Kagoshima, Sagamihara, Yokohama, Kanagawa
2025-01-08
Active, closed
Pfizer
Phase 3
200
Kobe, Nishinomiya, Osaka, Shibuya-ku, Kai, Kagoshima
2024-11-15
Active, closed
Ipsen
Phase 2
670
Fukuoka, Hiroshima, Hyōgo, Kagoshima, Kyoto, Miyagi, Osaka, Shizuoka
2024-10-10
Active, closed
Hoffmann-La Roche
Phase 3
400
Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima, Kanagawa, Nagasaki
2024-09-17
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Chiba, Chūōku, Fukuoka, Fukushima, Hidaka-shi, Isesaki-shi, Kagoshima, Kyoto
2024-08-13
Active, closed
Genmab
Phase 3
379
Toyoake, Matsuyama, Fukuoka, Fukushima, Sapporo, Amagasaki, Kagoshima, Isehara
2024-08-13
By invitation
Novo Nordisk A/S
Observational
23
Toshima City, Aomori, Fukuoka, Hokkaido, Kagoshima, Kanagawa, Kitakyusyu-shi, Fukuoka, Okinawa
2024-08-08
Recruiting
AstraZeneca
Phase 3
788
Chiba, Hidaka-shi, Hirakata-shi, Isehara-shi, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2024-08-01
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Nagoya, Chiba, Kashiwa, Matsuyama, Fukuoka, Sapporo, Kanazawa, Kagoshima
2024-07-19
Recruiting
Boehringer Ingelheim
Phase 1/2
768
Aichi, Nagoya, Isehara, Kagoshima, Kanagawa, Yokohama, Kashiwa-shi, Kyoto, Osaka, Tokyo, Koto-ku
2024-06-28
Active, closed
Cytokinetics
Phase 2/3
65
Kagoshima, Osaka, Sagamihara, Suita, Tokyo
2024-05-29
Recruiting
Boehringer Ingelheim
Phase 2
175
Akita, Amagasaki-shi, Fukuoka, Fukushima, Hachioji-shi, Kagawa, Kita-gun, Kagoshima, Kashihara
2024-05-15
Active, closed
GlaxoSmithKline
Phase 4
1,358
Fukuoka, Gifu, Hiroshima, Hyōgo, Kagawa, Kagoshima, Kanagawa, Kumamoto
2024-04-16
Recruiting
Otsuka Medical Devices Co., Ltd. Japan
Phase 1/2
49
Fukuoka, Sapporo, Kagoshima, Miyazaki, Nagasaki
2024-04-01
Recruiting
Eli Lilly and Company
Phase 3
90
Bunkyō City, Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya-ku
2024-03-13
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Hirosaki, Kagoshima, Kashiwa-shi, Kobe, Saga, Sendai, Setagaya Ku, Tokyo
2024-03-13
Active, closed
AbbVie
Observational
250
Matsuyama, Asahikawa, Hakodate-shi, Ryūgasaki, Tsukuba, Kagoshima, Kyoto, Sendai
2023-11-30
Active, closed
BeOne Medicines
Phase 3
652
Nagoya, Chiba, Matsuyama, Sapporo, AmagasakiCity, Kagoshima, Iseharashi, Sendai
2023-11-11
Not yet open
WONDER-02 Trial: Plastic Stent vs. Lumen-apposing Metal Stent for Pancreatic Pseudocysts
NCT06133023Pancreatic Fluid Collection, Pancreatitis, Pancreatic Pseudocyst
Tokyo University
Not applicable
80
Aichi, Bunkyō-Ku, Tokyo, Chiba, Fukuoka, Gifu, Hyōgo, Kagawa, Kagoshima
2023-11
Active, closed
Incyte Corporation
Phase 1
160
Chiba-ken, Kagoshima, Osaka, Tokyo, Tsu
2023-09-25
Recruiting
AstraZeneca
Phase 3
800
Fukuoka, Ginowan-shi, Hidaka-shi, Kagoshima, Kōtoku, Kurume-shi, Maebashi, Matsuyama
2023-09-22
Recruiting
Hoffmann-La Roche
Phase 3
230
Aichi, Chiba, Hiroshima, Kagoshima, Kanagawa, Kyoto, Matsuyama, Saitama
2023-09-08
Recruiting
Xenon Pharmaceuticals Inc.
Phase 3
360
Itami, Hamamatsu, Kagoshima
2023-05-09
Active, closed
Gilead Sciences
Phase 3
654
Aichi, Aoba-ku, Bunkyō City, Chiba, Chūōku, Ehime, Fukushima, Kagoshima
2023-05-08
Active, closed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
DrugGSK4532990
GlaxoSmithKline
Phase 2
284
Fukui, Fukuoka, Gifu, Hiroshima, Kagawa, Kagoshima, Kanagawa, Nagano
2023-01-02
Recruiting
Princess Maxima Center for Pediatric Oncology
Phase 3
160
Chiba, Ehime, Hiroshima, Hokkaido, Hyōgo, Kagoshima, Kanagawa, Kyoto
2022-12-15
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
100
Ehime, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima, Kanagawa
2022-11-04
Active, closed
Hoffmann-La Roche
Phase 3
68
Fukuoka, Hyōgo, Kagoshima, Kumamoto, Osaka, Tokyo
2022-11-01
Active, closed
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease
NCT05347095Fistulizing Crohns Disease, Perianal Crohns Disease
DrugGuselkumab
Janssen-Cilag Ltd.
Phase 3
288
Abiko, Chikushino-shi, Fukuoka, Fukuoka-ken, Hiroshima, Kagoshima, Kashihara, Kashiwa
2022-09-27
Active, closed
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 2
381
Asahikawa-shi, Chiba, Chūōku, Hiroshima, Kagoshima, Kawagoe-shi, Kita-gun, Sapporo
2022-09-16
Active, closed
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
NCT06696716Pemphigus, Steroid-resistant Pemphigus
DrugTirabrutinib
Ono Pharmaceutical Co., Ltd.
Phase 3
34
Aichi, Ehime, Fukuoka, Fukushima, Gunma, Hokkaido, Kagoshima, Kanagawa
2022-08-15
Recruiting
Immediate Necrosectomy vs. Step-up Approach for Walled-off Necrosis
NCT05451901Pancreatic Fluid Collection, Walled-off Necrosis, Pancreatitis, Acute Necrotizing, Pancreatic Pseudocyst
Tokyo University
Not applicable
70
Bunkyō-Ku, Aichi, Chiba, Gifu, Hyōgo, Kagawa, Kagoshima, Kamogawa
2022-07-29
Active, closed
Gilead Sciences
Phase 3
443
Aichi, Aoba-ku, Bunkyō City, Chūōku, Ehime, Fukushima, Inamachi, Kagoshima
2022-07-25
Active, closed
Gilead Sciences
Phase 3
623
Aichi, Bunkyō City, Chūōku, Ehime, Kagoshima, Kashiwa, Kōtoku, Kumamoto
2022-07-20
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
15
Aichi, Fukuoka, Fukushima, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima
2022-07-12
Active, closed
Hoffmann-La Roche
Phase 2/3
97
Hyōgo, Kagoshima, Shinjuku-ku
2022-06-02
Active, closed
AstraZeneca
Phase 3
644
Chūōku, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun, Kōtoku
2022-05-16
Active, closed
Sanofi
Phase 3
104
Sapporo, Kagoshima, Kawasaki, Sendai, Fukuoka, Tokyo
2022-05-03
Active, closed
BeOne Medicines
Phase 3
799
Matsuyama, Hiroshima, Sapporo, Kagoshima, Yokohama, KyotoShi, Okayama, Hirakata
2022-03-10
Recruiting
Pfizer
Phase 3
640
Kasuga-shi, Kiryu-shi, Higashinada-ku Kobe-shi, Nishinomiya-shi, Mito, Kagoshima, Kochi, Taihaku-ku Sendai-shi
2022-02-28
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Nagoya, Fukushima, Kobe, Nishinomiya-shi, Kagoshima, Kyoto, Miyazaki, Ōtsu
2022-01-13
Active, closed
Joseph Broderick, MD
Phase 3
860
Suita, Fukuoka, Gifu, Kagoshima, Kobe, Kyoto, Morioka, Niigata
2021-12-03
Active, closed
AstraZeneca
Phase 3
732
Chūōku, Fukuoka, Fukushima, Hiroshima, Isehara-shi, Kagoshima, Kashiwa, Kitaadachi-gun
2021-10-18
Active, closed
GlaxoSmithKline
Phase 3
40
Aichi, Chiba, Ehime, Fukuoka, Hiroshima, Hokkaido, Kagoshima, Kanagawa
2021-06-28
Active, closed
Extension Study of NS-089/NCNP-02 in DMD
NCT05135663Duchenne Muscular Dystrophy (DMD)
DrugBrogidirsen
Nippon Shinyaku Co., Ltd.
Phase 2
6
Kagoshima, Tokyo
2021-06-23
Active, closed
Daiichi Sankyo
Phase 2
155
Nagoya, Kashiwa, Sapporo, Chuo Ku, Fukuoka, Kagoshima, Kyoto, Nagasaki
2021-06-03
Active, closed
Biogen
Phase 3
158
Kagoshima, Bunkyō City
2021-05-17
Active, closed
Incyte Corporation
Phase 3
899
Fukuoka, Gifu, Ibaraki, Isehara, Kagoshima, Nagoya, Narita-shi, Okayama
2021-05-11
Active, closed
AstraZeneca
Phase 3
893
Chiba, Chūōku, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kōtoku, Kyoto
2021-05-10
Active, closed
Incyte Corporation
Phase 3
654
Fukuoka, Fukuyama-shi, Gifu, Kagoshima, Kashiwa-shi, Kitakyushu-shi, Kobe, Nagoya
2021-04-15
Recruiting
Pfizer
Phase 3
2,100
Kasuga-shi, Kiryu-shi, Higashinada-ku Kobe-shi, Nishinomiya-shi, Mito, Kagoshima, Taihaku-ku Sendai-shi, Abeno-ku Osaka-shi
2021-01-15
Active, closed
The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries
NCT04192747Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Elixir Medical Corporation
Not applicable
445
Kitakyushu, Kurume, Sapporo, Tsuchiura, Kagoshima, Kamakura, Kawasaki-shi, Yokohama
2020-12-16
Active, closed
Daiichi Sankyo
Phase 3
1,600
Akashi, Chūōku, Fukuoka, Hiroshima, Isehara, Kagoshima, Kashiwa, Kōtoku
2020-12-04
Active, closed
Eli Lilly and Company
Phase 3
312
Kagoshima, Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Shinjuku-ku, Tokyo
2020-11-25
Active, closed
Hoffmann-La Roche
Phase 3
992
Aichi, Chiba, Fukuoka, Hiroshima, Hokkaido, Hyōgo, Ibaraki, Kagoshima
2020-10-09
Active, closed
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
NCT04542824Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma
DrugsRituximab and lenalidomide·Gemcitabine and oxaliplatin·Epcoritamab·Lenvatinib
Genmab
Phase 1/2
78
Sendai, Aichi, Chiba, Ehime, Fukuoka, Fukushima, Kagoshima, Kyoto
2020-08-20
Active, closed
Actelion
Phase 3
935
Bunkyō City, Fukuoka, Hiroshima, Kagoshima, Kanagawa, Kanazawa, Kobe, Kurume
2020-06-30
Active, closed
AstraZeneca
Phase 3
818
Chiba, Fukuoka, Fukushima, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku
2020-04-16
Active, closed
Eli Lilly and Company
Phase 3
58
Bunkyō, Chiba, Kagoshima, Sendai, Takatsuki, Yokohama
2020-02-12
Active, closed
GlaxoSmithKline
Phase 2
25
Kagoshima, Kanagawa
2019-11-28
Active, closed
Novo Nordisk A/S
Phase 3
134
Aichi, Kagoshima, Kanagawa, Mie, Nara, Saitama, Tokyo
2019-10-21
Active, closed
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
NCT03811002Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
DrugsCis-platinum·CDDP·Tecentriq·Paraplatin
National Cancer Institute (NCI)
Phase 3
544
Sendai, Tōon, Sapporo, Kagoshima, Gunma, Niigata, Mitaka-shi, Hiroshima
2019-07-26
Active, closed
AstraZeneca
Phase 3
923
Bunkyō City, Fukuoka, Hidaka-shi, Hiroshima, Kagoshima, Kitaadachi-gun, Kōtoku, Kumamoto
2019-06-25
Active, closed
AbbVie
Phase 1
124
Obu-shi, Kobe, Kagoshima, Kawasaki-shi, Sendai, Niigata, Bunkyo-ku
2019-06-24
Recruiting
Eli Lilly and Company
Phase 3
190
Bunkyō, Chiba, Kagoshima, Kanazawa, Niigata, Saitama-shi, Sendai, Shinjuku-ku
2019-04-05
Active, closed
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
NCT03286634Down Syndrome, Acute Lymphoblastic Leukemia, Childhood Cancer
DrugsHydrocortisone·Mercaptopurine·Ara-C·Epirubicin
National Hospital Organization Nagoya Medical Center
Phase 2
60
Kagoshima
2017-04-18
Active, closed
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
NCT02502266Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
DrugsCediranib Maleate·Pegylated liposomal doxorubicin·Topotecan·Taxol
National Cancer Institute (NCI)
Phase 2/3
582
Tōon, Sapporo, Kagoshima, Koto-ku, Osaka, Saitama, Tokyo
2016-05-03
Active, closed
DS-3201b in Participants With Lymphomas
NCT02732275Lymphoma, Malignant, Non-hodgkin Lymphoma
DrugValemetostat Tosylate
Daiichi Sankyo Co., Ltd.
Phase 1
100
Nagoya, Kahiwa-shi, Morioka, Kagoshima, Kumamoto, Nagasaki, Nakagami-gun, Minato-ku
2016-03-31
Active, closed
National Cancer Institute (NCI)
Phase 3
579
Shiwa-gun, Kagoshima, Koto-ku, Saitama, Tokyo
2016-03-28
Active, closed
AstraZeneca
Phase 3
1,126
Akita, Bunkyō City, Fukuoka, Hakata-shi, Hirosaki-shi, Hiroshima, Izumo-shi, Kagoshima
2015-11-02
Active, closed
ETOP IBCSG Partners Foundation
Not applicable
518
Amagasaki, Hamamatsu, Fukuoka, Kagoshima, Kawasaki, Kyoto, Matsuyama, Minato-ku, Tokyo
2014-12-04
Active, closed
AstraZeneca
Phase 3
1,837
Chiba, Chūōku, Fukuoka, Hidaka-shi, Hiroshima, Isehara-shi, Kagoshima, Kashiwa
2014-04-22
Active, closed
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00565851Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
DrugsHD204·Bevacizumab-awwb·BP102·Zirabev
National Cancer Institute (NCI)
Phase 3
1,052
Sendai, Kure, Sapporo, Shiwa-gun, Kagoshima, Niigata, Shizuoka, Shinjuku-ku
2007-12-06
Recruiting
Medtronic
Observational
20,000
Ageo, Bunkyō City, Gifu, Hidaka, Hiroshima, Kagoshima, Kamakura, Kawasaki
1983-01
Rows per page Showing 1–108 of 108
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/kagoshima

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 108 of those studies with a site in Kagoshima.

How many clinical trials are recruiting in Kagoshima?

50 of the 108 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 2 have not yet opened recruitment, 55 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kagoshima), 108 studies
PhaseStudiesRecruitingShare
Phase 3713565.7%
Phase 215713.9%
Not applicable625.6%
Observational423.7%
Phase 2/3413.7%
Phase 1302.8%
Phase 1/2322.8%
Phase 4211.9%

Most active sponsors

Lead sponsors with the most studies (Kagoshima)
Lead sponsorStudiesRecruiting
AstraZeneca125
Eli Lilly and Company86
GlaxoSmithKline62
Hoffmann-La Roche62
AbbVie52
Janssen Research & Development, LLC55
Pfizer54
BeOne Medicines42
Incyte Corporation41
National Cancer Institute (NCI)40
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.